Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Occurrence of the BCR-ABL[superscript T315I] gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinati...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Other Authors: | , |
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group,
2014-08-26T12:05:55Z.
|
Subjects: | |
Online Access: | Get fulltext |